G protein-coupled receptors

G protein-coupled receptors
Name	G protein-coupled receptors

Contents

G protein-coupled receptors are a large family of membrane proteins that transduce extracellular signals into intracellular responses via heterotrimeric G proteins and downstream effectors. Emerging from foundational work by Paul A. M. Dirac, James Watson, Francis Crick, John Kendrew and contemporaries exploring protein structure, these receptors became central to understanding cell signaling through contributions from researchers at institutions such as Massachusetts Institute of Technology, Max Planck Society, Harvard Medical School and University of Cambridge. GPCR research intersects with discoveries recognized by awards including the Nobel Prize in Chemistry and has driven collaborations among pharmaceutical companies like Pfizer, GlaxoSmithKline, Novartis, and regulatory agencies including the Food and Drug Administration.

Introduction

GPCRs were first characterized during investigations into hormone action and vision by laboratories at University of Oxford, Columbia University, Stanford University, and University of California, San Francisco, and their study has been shaped by conferences such as the Gordon Research Conferences and journals like Nature and Science. The receptor superfamily includes rhodopsin-like receptors studied in contexts ranging from retinal research at Moorfields Eye Hospital to adrenergic signaling explored by teams at Rockefeller University and Johns Hopkins University. GPCR-related methodologies have been advanced by groups at European Molecular Biology Laboratory and technology firms like Illumina.

GPCRs share a seven-transmembrane helix architecture elucidated through structural biology efforts at facilities such as European Synchrotron Radiation Facility, Diamond Light Source, and Brookhaven National Laboratory. High-resolution structures were obtained by collaborations involving the Weizmann Institute of Science, Scripps Research Institute, and teams led by scientists affiliated with The Scripps Research Institute and University of California, San Diego. Classification schemes reference classes A (rhodopsin-like), B (secretin-like), C (metabotropic glutamate/pheromone), and others developed by consortiums including members from World Health Organization and International Union of Basic and Clinical Pharmacology. Structural motifs such as the DRY motif and NPxxY sequence were characterized by groups at University of Chicago and Yale University using techniques from American Society for Biochemistry and Molecular Biology meetings.

GPCR signaling involves activation of G proteins (Gs, Gi/o, Gq/11, G12/13) first described in biochemical studies at Cold Spring Harbor Laboratory, Institute Pasteur, and Karolinska Institutet. Signal transduction cascades engage effectors like adenylyl cyclases and phospholipase C, studied at Massachusetts General Hospital and Mayo Clinic, and intersect with second messengers such as cAMP and IP3 explored in work at University of Tokyo and Imperial College London. Regulatory processes including desensitization by GRKs and arrestins were delineated by teams at University of Pennsylvania and Beth Israel Deaconess Medical Center, and biased signaling concepts were advanced in collaborations involving University of Basel and industry partners like AstraZeneca.

GPCRs mediate senses and homeostasis across tissues from retina studies at Bascom Palmer Eye Institute to cardiovascular research at Cleveland Clinic and Mount Sinai Hospital. They regulate neurotransmission investigated at Columbia University Medical Center, hormonal axes examined at National Institutes of Health, and immune responses researched at Pasteur Institute and Dana-Farber Cancer Institute. Tissue-specific expression atlases produced by consortia including ENCODE Project and Human Protein Atlas map receptor distribution in organs studied at Karolinska University Hospital and Mayo Clinic, informing roles in processes central to organs such as kidney, liver, lung, and brain.

GPCRs are major targets in drug discovery programs at companies including Merck & Co., Roche, Bayer, and biotechnology firms collaborating with academic centers like University of Cambridge and University of Oxford. Ligand types include agonists, antagonists, inverse agonists, and allosteric modulators characterized in pharmacology departments at Johns Hopkins University and University College London. Screening platforms and structural-guided drug design leverage cryo-EM and X-ray crystallography facilities at Argonne National Laboratory and Rutherford Appleton Laboratory, and clinical translation follows pathways overseen by European Medicines Agency and Pharmaceutical Research and Manufacturers of America. Therapeutics targeting GPCRs span treatments for cardiovascular disease, psychiatric disorders, and metabolic conditions advanced at institutions such as Mount Sinai School of Medicine, Yale School of Medicine, and Columbia University.

Mutations and dysregulation of GPCRs underlie diseases investigated at hospitals and research centers including St. Jude Children's Research Hospital, Great Ormond Street Hospital, and Cleveland Clinic. Genetic studies from consortia like the Human Genome Project and 1000 Genomes Project have linked receptor variants to cancer, congenital disorders, and neurodegenerative diseases researched at Memorial Sloan Kettering Cancer Center and Salk Institute. Therapeutic strategies addressing receptor dysfunction involve approaches developed at Dana-Farber Cancer Institute, clinical trials coordinated through networks such as National Cancer Institute and regulatory review by Food and Drug Administration and European Medicines Agency. Ongoing translational research is supported by foundations including the Bill & Melinda Gates Foundation and the Wellcome Trust.